XERS:NASDAQXeris Biopharma Holdings, Inc. Analysis
Data as of 2026-08-31 - not real-time
$8.44
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind Xeris Biopharma Holdings, Inc. is bullish at $8.44, with short-term averages leading the long-term ones. It has lost 1.9% over the past 30 days. With RSI at 50.5 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $7.05 and resistance at $9.02.
The shares look undervalued, trading on 21.6 times earnings below a sector average of 30.4. The average analyst target implies 38.8% above today's level. Revenue is growing at 28.7% on a -5.1% profit margin.
Risk scores 7 out of 10, which is elevated for this asset class. With 30-day volatility of 48.1%, a beta of 0.77 and a maximum drawdown of 46.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to buy, carrying 6/10 conviction.
The shares look undervalued, trading on 21.6 times earnings below a sector average of 30.4. The average analyst target implies 38.8% above today's level. Revenue is growing at 28.7% on a -5.1% profit margin.
Risk scores 7 out of 10, which is elevated for this asset class. With 30-day volatility of 48.1%, a beta of 0.77 and a maximum drawdown of 46.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to buy, carrying 6/10 conviction.
Top Market Events
Xeris Biopharma Holdings Inc XERS posts a 29% revenue surge to $92.Xeris Biopharma’s August 6, 2026 update showed second-quarter revenue rising to US$92.The headline numbers for Xeris Biopharma XERS give insight into how the company performed in the quarter ended June...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 5/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 7.02
- MACD momentum is negative
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 21.6 versus sector average of 30.4
- Trading above the 200-day average of 7.02
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- P/E of 21.6 versus sector average of 30.4
- Negative profit margin of -5.1%
- Analyst targets imply +38.8% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth28.70%
Profit Margin-5.12%
P/E Ratio21.6
ROA6.13%
P/B Ratio-150.7
Op. Cash Flow$56.6M
Free Cash Flow$52.5M
Industry P/E30.4
Technical Analysis
TrendBullish
RSI50.5
Support$7.05
Resistance$9.02
MA 20$8.43
MA 50$8.29
MA 200$7.02
MACDBearish
VolumeDecreasing
Fear & Greed Index94.79
Valuation
Fair Value$9.07
Target Price$11.71
Upside/Downside38.79%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.77
Volatility48.06%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.